Robert Glanzman

1.6k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Robert Glanzman is a scholar working on Neurology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Robert Glanzman has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 6 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Robert Glanzman's work include Multiple Sclerosis Research Studies (6 papers), Polyomavirus and related diseases (3 papers) and Amyotrophic Lateral Sclerosis Research (3 papers). Robert Glanzman is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Polyomavirus and related diseases (3 papers) and Amyotrophic Lateral Sclerosis Research (3 papers). Robert Glanzman collaborates with scholars based in United States, Switzerland and Australia. Robert Glanzman's co-authors include Miroslav Bačkonja, David Leppert, Paul O’Connor, Ming Yin, Ludwig Kappos, Peter A. Calabresi, Frederik Barkhof, Amit Bar‐Or, Stephen L. Hauser and David Li and has published in prestigious journals such as The Lancet, Neurology and Annals of Neurology.

In The Last Decade

Robert Glanzman

14 papers receiving 1.0k citations

Hit Papers

Ocrelizumab in relapsing-remitting multiple sclerosis: a ... 2011 2026 2016 2021 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    2011 538 citations Ludwig Kappos, David Li et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Glanzman United States 9 529 354 292 221 156 14 1.1k
Volkmar Heidecke Germany 22 382 0.7× 288 0.8× 58 0.2× 119 0.5× 108 0.7× 42 1.3k
M. Carpo Italy 29 185 0.3× 1.8k 5.1× 180 0.6× 228 1.0× 108 0.7× 51 2.2k
Joachim Havla Germany 20 936 1.8× 559 1.6× 220 0.8× 63 0.3× 270 1.7× 66 1.3k
Paul Kwon United States 14 111 0.2× 55 0.2× 268 0.9× 360 1.6× 50 0.3× 18 923
Raeburn B Forbes United Kingdom 17 288 0.5× 475 1.3× 148 0.5× 50 0.2× 119 0.8× 26 1.0k
Jana Lízrová Preiningerová Czechia 14 700 1.3× 417 1.2× 257 0.9× 45 0.2× 132 0.8× 30 1.4k
Hongyu Zhou China 14 302 0.6× 248 0.7× 66 0.2× 55 0.2× 27 0.2× 76 681
W. Burkert Germany 20 288 0.5× 275 0.8× 21 0.1× 90 0.4× 94 0.6× 48 1.1k
Barbara Frigeni Italy 16 161 0.3× 196 0.6× 60 0.2× 138 0.6× 736 4.7× 25 1.2k
S. Jann Italy 18 63 0.1× 722 2.0× 45 0.2× 272 1.2× 184 1.2× 36 1.3k

Countries citing papers authored by Robert Glanzman

Since Specialization
Citations

This map shows the geographic impact of Robert Glanzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Glanzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Glanzman more than expected).

Fields of papers citing papers by Robert Glanzman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Glanzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Glanzman. The network helps show where Robert Glanzman may publish in the future.

Co-authorship network of co-authors of Robert Glanzman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Glanzman. A scholar is included among the top collaborators of Robert Glanzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Glanzman. Robert Glanzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Vucic, Steve, Parvathi Menon, William Huynh, et al.. (2023). Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. EClinicalMedicine. 60. 102036–102036. 30 indexed citations
2.
3.
Vucic, Steve, Toby A. Ferguson, Angela Genge, et al.. (2021). Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. Muscle & Nerve. 64(5). 532–537. 25 indexed citations
4.
5.
Curtin, François, et al.. (2016). A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design. Multiple Sclerosis and Related Disorders. 9. 95–100. 12 indexed citations
6.
Kappos, Ludwig, David K.B. Li, Peter A. Calabresi, et al.. (2012). Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006). Neurology. 78(Meeting Abstracts 1). S30.006–S30.006. 2 indexed citations
7.
8.
Kappos, Ludwig, et al.. (2012). Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply. The Lancet. 379(9822). 1197–1197. 1 indexed citations
9.
Leppert, David & Robert Glanzman. (2012). On being a neurologist in industry. Annals of Neurology. 73(3). 319–326. 1 indexed citations
10.
Zhang, Jiameng, Emmanuelle Waubant, Gary Cutter, Jerry S. Wolinsky, & Robert Glanzman. (2012). EDSS variability before randomization may limit treatment discovery in primary progressive MS. Multiple Sclerosis Journal. 19(6). 775–781. 15 indexed citations
11.
Kappos, Ludwig, David Li, Peter A. Calabresi, et al.. (2011). Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet. 378(9805). 1779–1787. 538 indexed citations breakdown →
12.
Sergott, Robert C., Elliot M. Frohman, Robert Glanzman, & Ahmad Al‐Sabbagh. (2007). The role of optical coherence tomography in multiple sclerosis: Expert panel consensus. Journal of the Neurological Sciences. 263(1-2). 3–14. 76 indexed citations
13.
Bačkonja, Miroslav & Robert Glanzman. (2003). Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clinical Therapeutics. 25(1). 81–104. 300 indexed citations
14.
Glanzman, Robert, Douglas J. Gelb, Ivo Drury, Mark B. Bromberg, & Daniel D. Truong. (1990). Brachial plexopathy after botulinum toxin injections. Neurology. 40(7). 1143–1143. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Volkmar Heidecke Breakdown of academic impact, for papers by M. Carpo Breakdown of academic impact, for papers by Joachim Havla Breakdown of academic impact, for papers by Paul Kwon Breakdown of academic impact, for papers by Raeburn B Forbes Breakdown of academic impact, for papers by Jana Lízrová Preiningerová Breakdown of academic impact, for papers by Hongyu Zhou Breakdown of academic impact, for papers by W. Burkert Breakdown of academic impact, for papers by Barbara Frigeni Breakdown of academic impact, for papers by S. Jann
Rankless by CCL
2026